Table 2.
Cost-utility ratios of providing RSV immunoprophylaxis to infants by risk group and by annual hospitalizations in children aged 0–2 years old (a)
| Risk Group | Annual hospitalizations in children aged 0–2 years | ||
|---|---|---|---|
| 2700 | 2945 | 3200 | |
| Cost per DALY including asthma | Cost per DALY including asthma | Cost per DALY including asthma | |
| CHD | $223,687 | $218,968 | $214,347 |
| CLD | $303,658 | $287,057 | $268,242 |
| <29 | $246,594 | $226,900 | $208,765 |
| 29–32 | $369,551 | $347,593 | $327,141 |
| 33–36 | $1,211,273 | $1,149,584 | $1,092,860 |
| No risk | $3,217,414 | $3,023,294 | $2,849,644 |
acost-effectiveness threshold is $105,986 per averted DALY